<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653599</url>
  </required_header>
  <id_info>
    <org_study_id>TTP273-201</org_study_id>
    <nct_id>NCT02653599</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, randomized, double-blind, placebo-controlled parallel group,
      Phase 2 study in subjects with Type 2 diabetes mellitus on a stable dose of metformin to
      evaluate the safety and efficacy of TTP273 versus placebo glucose control and body weight
      following administration for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieve HbA1c &lt;7% at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose levels from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid Levels from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin levels from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide levels from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram Parameters</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Day 1 to Week 14</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in glucagon levels from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in glucagon-like peptide-1 levels from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TTP273 300 mg daily (150 mg BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTP273 150 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two matching placebo tablets administered orally twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP273</intervention_name>
    <arm_group_label>TTP273 300 mg daily (150 mg BID)</arm_group_label>
    <arm_group_label>TTP273 150 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>TTP273 150 mg daily</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and
             meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus.

          -  On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for
             the last 3 months prior to screening.

          -  Males. Females of non-childbearing potential.

          -  Generally stable health without a history of major surgery or significant injuries
             within the last year and without an active infection.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young,
             insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus,
             or history of diabetic ketoacidosis.

          -  Participation in a clinical trial and receipt of an investigational product within 30
             days.

          -  Participation in any formal weight loss program, or fluctuation of &gt; 5% in body
             weight, or having received medications approved for weight loss within 3 months prior
             to screening or contemplating such therapy during the trial.

          -  Previous surgical treatment of obesity.

          -  Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice
             administered by someone other than the patient within 6 months prior to screening.

          -  Use of other diabetic agents except metformin within 3 months prior to Screening.

          -  History of pancreatitis.

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screening.

          -  History of hemolytic anemia, chronic transfusion requirement or other condition
             rendering HbA1c results unreliable.

          -  History of MEN-2 or family history of medullary thyroid cancer.

          -  History or presence of clinically significant disease (other than Type 2 diabetes
             mellitus).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Freeman, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>vTv Therapeutics LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <disposition_first_submitted>February 9, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 10, 2017</disposition_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

